The PEACE 5 and PANTHEON 6 studies have shown that the longer the treatment duration, the better is the outcome that the patients would have
doi: 10.1056/NEJMoa2407379
Yarizadh H, Shab-Bidar S, Zamani B, Vanani AN, Baharlooi H, Djafarian K
The drug candidate acts as an agonist of the glucagon-like peptide-1 (GLP-1) receptor, following the same mode of action as Mounjaro (tirzepatide), the companys peptide-based GLP-1 drug for weight loss
The rationale cited was allowing time for structural synaptic changes to consolidate between administrations while avoiding potential receptor desensitization
Another key thing about the wanting system and arguably, its most frustrating aspect is that it often exists beyond our conscious awareness